Sangamo Therapeutics, Inc.
(NASDAQ : SGMO)

( )
SGMO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.58%86.501.3%$1352.34m
AMGNAmgen Inc.
-0.21%201.561.2%$603.80m
GILDGilead Sciences, Inc.
0.72%68.740.9%$538.95m
LOXOLoxo Oncology Inc
-0.03%233.7012.7%$517.58m
BIIBBiogen Inc.
-0.51%337.221.3%$412.55m
VRTXVertex Pharmaceuticals Incorporated
-2.06%189.891.9%$326.56m
ILMNIllumina, Inc.
-0.44%302.293.5%$303.21m
REGNRegeneron Pharmaceuticals, Inc.
-0.88%401.212.6%$300.94m
ALXNAlexion Pharmaceuticals, Inc.
2.37%117.002.0%$223.30m
EXASExact Sciences Corporation
4.79%79.7125.3%$149.33m
AAgilent Technologies, Inc.
0.45%71.641.5%$147.28m
INCYIncyte Corporation
-2.75%75.202.5%$143.98m
SRPTSarepta Therapeutics, Inc.
-1.30%118.7215.4%$129.31m
LGNDLigand Pharmaceuticals Incorporated
-1.00%111.7823.1%$119.93m
NBIXNeurocrine Biosciences, Inc.
-2.15%89.325.1%$95.56m

Company Profile

Sangamo Therapeutics, Inc. researches and develops transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II on June 22, 1995 and is headquartered in Richmond, CA.